• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    GlycoMimetics to Present at Upcoming Healthcare Investor Conferences

    Chelsea Pratt
    Nov. 10, 2016 07:01AM PST
    Biotech Investing

    GlycoMimetics today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week.

    GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows:

    STIFEL 2016 HEALTHCARE CONFERENCE
    WHEN: NOVEMBER 15,
    2016 AT 4:30 PM ET
    WHERE: NEW YORK, NY, USA

    JEFFERIES 2016 LONDON HEALTHCARE CONFERENCE
    WHEN: NOVEMBER
    17, 2016 AT 1:20 PM GMT
    WHERE: LONDON, UK

    To access the live webcast and subsequent archived recordings for the
    presentation, please visit the GlycoMimetics website at www.glycomimetics.com.
    About GlycoMimetics, Inc.
    GlycoMimetics is a clinical-stage biotechnology company focused on
    cancer and sickle cell disease. GlycoMimetics’ most advanced drug
    candidate, rivipansel, a pan-selectin antagonist, is being developed for
    the treatment of vaso-occlusive crisis in sickle cell disease and is
    being evaluated in a Phase 3 clinical trial being conducted by its
    strategic collaborator, Pfizer. GlycoMimetics’ wholly-owned drug
    candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an
    ongoing Phase 1/2 clinical trial as a potential treatment for AML and in
    a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also
    recently initiated a clinical trial with a third drug candidate,
    GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
    located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com

    healthcare conferencesickle cell diseasedrug candidate
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×